Swedish Orphan Biovitrum AB’s (publ) (http://www.sobi.com) (Sobi™) CEO Geoffrey
McDonough has divested 230,000 of the shares he holds in the company. The sale
was made in part to pay the estimated US tax due relating to the vesting of the
company’s 2013 long-term incentive programme, and to prepare to invest in the
upcoming 2016 long-term incentive programme should it be approved by the Annual
General Meeting later this month.
The 2013 long-term incentive programme has met its objectives and will vest in
full. Geoffrey McDonough will receive 135,000 shares under this programme. After
the transactions, the CEO will hold a total of 647,845 shares in the company.
When receiving incentive shares, their fair market value will be taxed as income
at the time of allotment. In the US preliminary tax must be remitted on the
allotment date.
---
Terms and conditions of the proposed Sobi 2016 Executive long-term incentive
program can be found on www.sobi.com.
About Sobi™
Sobi™ is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of speciality and rare disease products across Europe, the Middle
East, North Africa and Russia for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion
(USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on
NASDAQ Stockholm.
For more information please contact
Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice
Communications President, Head of Investor
Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212
-579-0506, +46 8 697 2135
oskar.bosson@sobi.com jorgen.winroth@sobi.com
The information set out in this press release is announced in accordance with
the Swedish Securities Market Act. The information was submitted for publication
on 16 May 2016 at 08:30 CET.
